1. Hormone facility startup - Commercial production began June 30, 2026 at the Bhayla women's hormone plant (₹130 cr capex, 19.4 crore tablets/capsules annual capacity), with EU-GMP certification already in hand. Management expects asset turnover to rise from under 1 in FY27 to 2-3 over three years, and international dossiers are set for filing by November-December 2026.
2. Wokadine brand scale-up - Acquired from Dr. Reddy's on March 30, 2026 for ₹97 cr, Wokadine is ranked #2 in India's ₹648 cr Povidone Iodine market and brings a ₹20 cr internal revenue base. Management targets 25% annual growth for 3-4 years to double the brand to ₹40 cr, with the ₹2.5 cr quarterly amortization already absorbed.
3. Bayer Zydos portfolio relaunch - Seven brands acquired from Bayer Zydus in July 2025, including Noklot (anti-platelet, ₹1,500+ cr market) and fertility brands Menodac and Fostine R; Noklot launched June 2026 with ₹7 cr revenue recovered in Q1. Management targets ₹50-100 cr for the portfolio first, then scaling individual brands.
4. Semaglutide GLP-1 entry - Launched Wyntide and Tyvenza in FY26 with manufacturing partner MSM, one of only two-three companies with access; management anticipates a market of ₹2,000-2,500 cr. Management targets a top-10 position in a market where India has \~10 crore eligible patients.
5. IVF task force - Dedicated task force established in Q4 FY26 focused on infertility specialists and IVF hospital chains, started generating business in Q1 FY27. This is the fourth women's healthcare theme, built on the Bayer Zydus fertility portfolio and India's growing IVF market.
6. MR force expansion - Added \~450 medical representatives in FY26 (total \~3,100), with existing multi-specialty divisions split into three to increase focus. Per-rep productivity rises with tenure (₹2 lakh/month at 0-3 years to ₹6-8 lakh at 6+ years), so the recent hires mature into higher output.
7. Bhayla capacity addition - Additional 40 crore tablets/capsules capacity commissioned December 22, 2025, funded entirely from internal accruals, raising installed capacity to \~184 crore units. This removes the capacity constraint at 93.6% utilization and supports the 15%+ organic growth target.
8. La Chandra API integration - 31% associate stake supplies \~60-65% of Corona's hormone API consumption, including \~65% of India's progesterone; EU GMP plant kicks off by early Q3 FY27. This backward integration secures API supply and margins as the hormone facility ramps.
9. International hormone push - International business (currently \~3.5% of revenue) targets high single-digit (8-9%) CAGR over 3-4 years, with 15 products in the pipeline and EAEU GMP certification received January 2026. The Bhayla hormone plant's dossiers for Europe/UK are expected to kick off international revenue in FY28-29.